Servier $2.65B Muscular Dystrophy Asset Deal
Decision brief
Answer first · skim in under a minute
French pharmaceutical giant Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for an upfront payment of $1.55 billion, with potential milestone payments reaching up to $2.7 billion. This strategic move significantly expands Servier's footprint in the rare disease and neurology space.
Servier bought Edgewise Therapeutics' muscular dystrophy business—led by sevasemten—for $1.55 billion upfront and up to $1.1 billion in milestones, or $2.65 billion total. The June 1, 2026 deal closed July 10, 2026, shifting Edgewise fully toward its cardiovascular pipeline after years of Becker and Duchenne development.
Contents10 sections
Key Takeaways
- Upfront cash is $1.55 billion; milestones add up to $1.1 billion for a $2.65 billion ceiling—not $2.7 billion.
- Asset is sevasemten (EDG-5506), a late-stage oral myosin inhibitor for Becker and Duchenne muscular dystrophy.
- GRAND CANYON (NCT05291091) is fully enrolled with 175 participants in the pivotal Becker cohort; Edgewise guided to Q4 2026 top-line data at announcement.
- Closing completed July 10, 2026 per Edgewise's Form 8-K; Edgewise pivots to EDG-7500, EDG-15400, and EDG-003.
What did Servier acquire and at what price?
Servier Pharmaceuticals LLC and Les Laboratoires Servier acquired sevasemten and related muscular dystrophy assets under an asset purchase agreement announced June 1, 2026 (agreement dated May 31, 2026). Consideration is $1.55 billion cash at closing plus up to $1.1 billion in milestones.
Edgewise detailed the structure in its June 1, 2026 PR Newswire release and later closing filings. The buyer also took key program know-how, filings, and offered roles to MD-focused Edgewise staff.
When did the deal close?
Edgewise reported completion on July 10, 2026, in a Form 8-K, with a July 13, 2026 press release. Closing followed HSR clearance and customary conditions after a planned third-quarter 2026 window.
Primary closing disclosure is on Edgewise's SEC Form 8-K. Servier separately confirmed completion in a July 13, 2026 PR Newswire statement.
Why is sevasemten strategically valuable?
Sevasemten is designed to limit contraction-induced damage in dystrophin-deficient muscle. Edgewise said it would be the first therapy indicated for Becker muscular dystrophy if approved, citing about 12,000 affected people across the U.S., EU-5, and Japan.
- $1.55 billion upfront cash
- Up to $1.1 billion milestones
- $2.65 billion aggregate potential
- 175 participants in GRAND CANYON pivotal Becker cohort
- NCT05291091 for CANYON / GRAND CANYON
The 8-K for the announcement also maps U.S. approval milestones, including up to $200 million for specified Becker labeling and $600 million for Duchenne U.S. approval—terms investors should read in the filing, not paraphrase from secondary coverage.
What do the clinical programs show so far?
CANYON / GRAND CANYON (NCT05291091) is a Phase 2 randomized, placebo-controlled study of sevasemten in Becker muscular dystrophy, with an expanded pivotal GRAND CANYON cohort. Edgewise said GRAND CANYON was fully enrolled and powered above 98% for NSAA versus placebo at announcement.
Trial registry details are on ClinicalTrials.gov NCT05291091. Company materials also cite MESA open-label extension experience and Phase 2 Duchenne studies (for example LYNX), but those do not change the deal economics.
How does the deal reshape Edgewise?
After closing, Edgewise is a cardiovascular company. Retained programs include EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003. Management said upfront proceeds plus cash should fund EDG-7500 through potential approval.
At announcement, Edgewise also pointed to 12-week CIRRUS-HCM Part D data for EDG-7500 in Q2 2026 and a targeted Phase 3 start in Q4 2026—milestones now separate from the Servier MD franchise.
What remains unproven?
Sevasemten is not FDA- or EMA-approved. GRAND CANYON top-line results were still pending at close. Milestone cash depends on future labels and sales that are not guaranteed. Do not treat the $2.65 billion headline as cash already received beyond the $1.55 billion upfront. Competitors in Duchenne gene therapy and exon skipping remain separate commercial realities from this asset sale.
Related NovaPharma coverage
- Muscular dystrophy disease profile
- Edgewise Therapeutics company profile
- AbbVie Cerevel neuroscience acquisition
Frequently Asked Questions
What did Servier pay for Edgewise's muscular dystrophy assets?
Servier paid $1.55 billion in upfront cash and may owe up to $1.1 billion in regulatory and commercial milestones, for aggregate potential consideration of up to $2.65 billion, per Edgewise's June 1, 2026 announcement and July 2026 closing 8-K.
What is sevasemten and which trials matter most?
Sevasemten (EDG-5506) is an oral fast skeletal myosin inhibitor in late-stage study for Becker and Duchenne muscular dystrophy. The GRAND CANYON pivotal cohort in Becker is registered as NCT05291091, with company guidance pointing to top-line data in the fourth quarter of 2026.
What does Edgewise keep after the sale?
After closing on July 10, 2026, Edgewise remains a cardiovascular-focused company advancing EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003, funded in part by the $1.55 billion upfront proceeds.
Primary Sources
Servier pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
